**Supplemental Table 2**. Adverse Events Leading to Treatment Discontinuation in the All-Treated Set

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | PBO n=101 | ASN  2.5 mg bid n=97 | ASN 5 mg bid n=113 | OLZ 15 mg qd n=46 |
| System organ class, preferred term, n (%) | | | | |
| Patients with an AE leading to treatment discontinuation | 10 (9.9) | 10 (10.3) | 14 (12.4) | 1 (2.2) |
| Psychiatric disorders | 8 (7.9) | 9 (9.3) | 10 (8.8) | 1 (2.2) |
| Schizophrenia | 4 (4.0) | 5 (5.2) | 4 (3.5) | 0 (0.0) |
| Psychotic disorder | 2 (2.0) | 4 (4.1) | 2 (1.8) | 1 (2.2) |
| Anxiety | 1 (1.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| Psychiatric symptom | 1 (1.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| Aggression | 0 (0.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| Mental disorder | 0 (0.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| Nervous system disorders | 1 (1.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| Epilepsy | 1 (1.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Psychomotor hyperactivity | 0 (0.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| Skin and subcutaneous tissue disorders | 0 (0.0) | 1 (1.0) | 1 (0.9) | 0 (0.0) |
| Alopecia | 0 (0.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| Rash | 0 (0.0) | 1 (1.0) | 0 (0.0) | 0 (0.0) |
| Gastrointestinal disorders | 0 (0.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| Small intestine obstruction | 0 (0.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| Injury, poisoning, and procedural complications | 1 (1.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Road traffic accident | 1 (1.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Musculoskeletal and connective tissue disorders | 0 (0.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| Myalgia | 0 (0.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| AE, adverse event; ASN, asenapine; bid, twice daily; OLZ, olanzapine; PBO, placebo; qd, once daily.  Adverse events were coded using the MedDRA dictionary version 17.0.  The denominator for percentages is the number of patients in each treatment group.  Patients were counted only once within each system organ class and preferred term. | | | | |